|Day's Range||70.35 - 71.55|
|52 Week Range||37.05 - 82.00|
|PE Ratio (TTM)||-12.49|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients in Europe.
The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients (mostly males) in Europe.
New drugs from Novartis and Alexion won a green light from European regulators on Friday, delivering a boost to both drugmakers and offering new treatment options for cancer and rare diseases. Experts from the European Medicines Agency (EMA) said they had recommended approval of Novartis's Farydak for multiple myeloma, an aggressive blood cancer, and Odomzo for basal cell carcinoma, a type of skin cancer.